Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.
about
Determining Linezolid's baseline in vitro activity in Canada using gram-positive clinical isolates collected prior to its national release.Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistanceIn vitro activities of the Rx-01 oxazolidinones against hospital and community pathogensPotential role of tedizolid phosphate in the treatment of acute bacterial skin infectionsAll great truths are iconoclastic: selective decontamination of the digestive tract moves from heresy to level 1 truth.A review of linezolid: the first oxazolidinone antibiotic.In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureusIdentification, cloning, and functional characterization of EmrD-3, a putative multidrug efflux pump of the major facilitator superfamily from Vibrio cholerae O395Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of AmericaWhat action should be taken to prevent spread of vancomycin resistant enterococci in European hospitals?In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria.Response to emerging infection leading to outbreak of linezolid-resistant enterococci.Whole genome analysis of linezolid resistance in Streptococcus pneumoniae reveals resistance and compensatory mutations.Vancomycin for the treatment of methicillin-resistant staphylococcal and enterococcal infections in 15 horsesIn vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates.In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium sppIn vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program.In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.Vancomycin-resistant enterococci: mechanisms and clinical observations.Comparison of testing methods for detection of decreased linezolid susceptibility due to G2576T mutation of the 23S rRNA gene in Enterococcus faecium and Enterococcus faecalis.Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage.Antibiotic prophylaxis in patients receiving hematopoietic stem cell transplant.Therapies in development for community-acquired pneumonia.Vancomycin resistance: small molecule approaches targeting the bacterial cell wall biosynthesis.Linezolid-resistant Staphylococcus aureus strain 1128105, the first known clinical isolate possessing the cfr multidrug resistance gene.Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review.Update on the safety of linezolid.High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The NetherlandsLEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.Vancomycin resistance: occurrence, mechanisms and strategies to combat it.Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection.The use of dyes in modern biomedicine.Daptomycin.Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).Treatment and prevention of enterococcal infections--alternative and experimental approaches.Enterococcus faecalis resistant to linezolid: case series and review of the literature.Antimicrobial resistance to linezolid.Antibiotic resistance in the intensive care unit setting.Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients.
P2860
Q24535971-C683B68E-DA53-4E88-90A4-A9DB517FE4FBQ24655140-9D64D09E-D783-4936-A59E-6B81CB1C1A7CQ24656140-DBAE528A-EE81-41C4-BC8F-9DD8A233A36AQ26853612-3232FB21-03C2-43AB-8675-141DD528B518Q30332721-FA15D33D-07AE-4B6C-8108-DF9083A0A207Q33363226-2F0C8BF2-6CD1-42AF-AA5D-0D95B056A2AFQ33556476-0CB837B1-ADDC-4EA4-9D10-12516A0B3035Q33603996-BE01AD9B-3B97-4BD7-8BAD-F3E6ED471122Q33688646-2F83AEC2-CA55-4862-9874-37279C246DB9Q33809563-3AB05F1D-F236-4077-A71B-E9A0C5EBBCB2Q33836608-39B78EC2-BFB8-402C-9EC9-C5CC2768612CQ33884094-78C18610-4536-448E-BAD7-7E24FA4AF1B2Q34049640-8679B10B-E8FD-4A2C-84AA-D323BC74CED0Q34075738-12363BF5-BB0B-445F-AD5E-85D82AFE9EABQ34110412-375924A2-FF11-42F6-9902-E20C4095036CQ34111344-4A65B910-9791-46EB-BD3D-E47839D3851EQ34141027-222F5BE3-D1F0-4937-AD37-AAFC909E9F1DQ34228269-73ECD0CB-1394-47AE-8BC9-102262122E76Q34252432-760E64CD-70BE-4C38-B69C-AD2FA56EB05CQ34289227-71282A91-CB9D-4129-8A74-937213EA1932Q34431930-70AA32DE-786A-4C35-BE6C-CF8CA6484FBFQ34431963-A41F59F1-BA13-4A9F-BA48-498D44AF3D73Q34580312-EBAD1E3F-FB7E-4806-8687-594172D60692Q34581508-FE96A021-7E6B-4C15-A497-301F7A829BE9Q34587629-68009ABA-73FB-47E3-AD50-3368545CA1F1Q34596580-8204D1E5-5D84-45C9-B95A-F2036B5FC2B2Q34871254-BAADA44E-4475-41AD-8882-4EE7D34B616EQ34987632-72F7D53D-D679-400D-9F19-79B094040E8FQ35027895-E156E239-BE5C-4BB2-97E3-F04B870E3625Q35139437-34BC11CD-7787-435A-9D6B-DD750C9F47C9Q35143886-F4129E12-1A24-4534-994B-A8730650D159Q35215431-916E4EAB-ABE6-4FFD-BCA6-0139D6122435Q35625144-D7C3D617-C965-4AB7-BD1E-87BED7DE13BCQ35637066-FCF24FFD-3B09-45D1-A377-1F36288293FDQ35782816-C149192E-0615-49FA-95C0-A563F207ACC5Q35873796-FF9B3379-C4A9-4A4E-9DCB-FDCC4955B8D1Q35906331-3196FED2-76D1-4C97-B1DB-E0F9F25ADCF6Q35912430-17649ABA-3545-4BF6-801F-8522C62DF469Q35917198-75E6DA9C-F353-4083-815D-98A5CAD4F64FQ35933388-FC006DF0-9DB7-4171-996B-9501EBDF6E49
P2860
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.
@en
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.
@nl
type
label
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.
@en
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.
@nl
prefLabel
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.
@en
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.
@nl
P2093
P1433
P1476
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.
@en
P2093
K DenBesten
M B Graham
P C Schreckenberger
R D Gonzales
P356
10.1016/S0140-6736(00)04376-2
P407
P577
2001-04-01T00:00:00Z